Sport Concussion (mTBI) and ongoing monitoring will be a major focus of Neural Diagnostics this year

The first Proprietary prototype EVestG Unit costing $1.3M will commence clinical trials in April at the Monash Alfred Psychiatry Research Centre (MAPrc) at the Alfred Hospital in Melbourne. Early trials will look at concussion (mTBI) in Sport and the monitoring of any long term effects. Research will also be undertaken in respect of road trauma. A prestigious NHMRC fellowship has already been awarded to a highly respected researcher working in conjunction with Neural to evaluate EVestG’s application to monitoring recovery from mTBI. The research being undertaken in respect of mTBI will also be closely related to Depression and Post Traumatic Stress Disorder in war conflict situations.

The data compilation programme in respect of Major Depression, Bipolar and schizophrenia will continue at MAPrc  in addition to this mTBI study. The second EVestG unit operating at the University of Manitoba in Canada is undertaking the application of EVestG to the early diagnosis of Alzheimer’s.

Supported by the Victorian Governments STIUCC programme with a grant of $50,000 design and development work has commenced in conjunction with Minifab on a prototype proprietary electrode sensor for use by the EVestG technology, but with potential for use by ECOG and similar.

Application for regulatory Therapeutic Goods Registration (class 2A) approval of this disruptive technology will commence in September of this year.

Neural Diagnostics is seeking further capital of $600,000 to conclude the current work programme relating to the commissioning of the new EVestG unit, the improvement of the various algorithms relating to the analysis of recorded raw data, data compilation and calibration, in vivo animal research, and completion of analysis of fundamental scientific literature reporting research on the vestibular and its relationship to the behavioural and emotive sections of the brain as reflected through neural transmitters.